Stock go up, investor happy. Stock go down, investor… sad?
Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small cell lung cancer (NSCLC). The data was positive …
Analyst Alex Arfaei of BMO Capital downgraded his rating on Merck & Co., Inc.
Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck …
This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE:WX), led a $15 million Series …
On December 8th, Merck & Company (NYSE: MRK) announced plans to buy Cubist Pharma (NASDAQ: CBST) for a total transaction value of $9.5 billion.
Entry: $9.86 10/2/14 Take Profits: $14.
West Pharmaceutical Services (WST) is an example of a good stock in a good sector. I like the health care sector in the …
